Patents Examined by Ganapathy Krishnan
  • Patent number: 10246477
    Abstract: The present invention relates to isomerization of C4-C6 aldoses to their corresponding C4-C6 ketoses. In particular, the invention concerns isomerization of C4-C6 aldoses over solid zeolite catalysts free of any metals other than aluminum, in the presence of suitable solvent(s) at suitable elevated temperatures. C6 and C5 aldose sugars such as glucose and xylose, which are available in large amounts from biomass precursors, are isomerized to fructose and xylulose respectively, in a one or two-step process over inexpensive commercially available zeolite catalysts, containing aluminum as the only metal in the catalyst. The ketoses obtained are used as sweeteners in the food and/or brewery industry, or treated to obtain downstream platform chemicals such as lactic acid, HMF, levulinic acid, furfural, MMHB, and the like.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: April 2, 2019
    Assignee: DANMARKS TEKNISKE UNIVERSITET
    Inventors: Anders Riisager, Shunmugavel Saravanamurugan
  • Patent number: 10239961
    Abstract: The invention provides a method for preparing sulphoalkyl ether-?-cyclodextrin. The method comprises first contacting cyclodextrin with a base to form activated cyclodextrin. The method then comprises separately contacting the activated cyclodextrin with an alkyl sultone to form sulphoalkyl ether-?-cyclodextrin. The activation reaction is carried in batch and the sulphoalkylation reaction is carried out under continuous flow conditions.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 26, 2019
    Assignee: CURADEV PHARMA PRIVATE LIMITED
    Inventors: Tammy Savage, Stephen Wicks, John Mitchell
  • Patent number: 10238676
    Abstract: The present invention discloses an application of ginsenoside Rg3 in preparing a medicine or product for preventing and treating dementia, and a preparation method thereof, which belong to the fields of medicines and health care products, and its products comprise a topical preparation, oral preparation and injection of the ginsenoside Rg3; and the Rg3 medicine or formulating prepared Rg3 compound medicine is prepared by using a solubilizer, a transdermal agent, a reagent promoting the absorption by penetrating a blood-brain barrier and an extractive, achieving the effect that the medicine penetrates the blood-brain barrier, and is used for preventing and treating dementia.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 26, 2019
    Inventor: Li Fu
  • Patent number: 10213521
    Abstract: A purified and sterilized polysaccharide that exhibits enhanced and extended shelf life over conventionally prepared polysaccharides for biomedical applications. The polysaccharide, upon crosslinking, forms a hydrogel that functions as a protective coating or on tissue and structures in the ears, nose, throat, limbs and spinal column.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 26, 2019
    Assignee: MEDTRONIC XOMED, INC.
    Inventors: Jie Wen, Denise E. Guenther, Dana A. Oliver
  • Patent number: 10188674
    Abstract: Pharmaceutical compositions adapted for the parenteral administration, including intravenous administration, of triazole containing macrolide antibiotics, and methods for their use in the treatment of bacterial, protozoal, and other infections are described herein.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 29, 2019
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventors: David E. Pereira, Sara Wu, Prabhavathi Fernandes
  • Patent number: 10183964
    Abstract: Provided are cyanogenic compositions for treating diseases, such as infectious diseases.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 22, 2019
    Inventor: Laszlo Sichtnik
  • Patent number: 10183038
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 22, 2019
    Assignee: L&F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10174006
    Abstract: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: January 8, 2019
    Assignee: NOVARTIS AG
    Inventors: Malay Ghosh, Christopher Michael Adams, Stephanie Kay Dodd, Stephen Hedrick Poor
  • Patent number: 10174132
    Abstract: The invention provides an efficient modular chemical synthesis for heparan sulfate oligosaccharides based on orthogonal protection strategies. Modular disaccharide building blocks, themselves the product of a novel combinatorial synthesis, are combined in numerous ways to produce a range of oligosaccharides.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 8, 2019
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Geert-Jan Boons, Andre Venot, Sailaja Arungundram, Kanar al-Mafraji
  • Patent number: 10172353
    Abstract: The present invention provides a composition comprising (i) chitosan or chitopoly- or chitooligo-saccharides thereof, wherein said chitosan or chitopoly- or chitooligo-saccharides thereof comprise ?-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine monomers and have a degree of acetylation between 0.05 and 0.20 and an average degree of polymerization ?250 (molecular weight ?42,000 Da), and (ii) a fungicide not containing chitopoly- or chitooligo-saccharides.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: January 8, 2019
    Assignee: BIOCHOS AS
    Inventors: Arne Tronsmo, Berit Bjugan Aam, Linda Hjeljord, Morten Sorlie, Md Hafizur Rahman, Anne Line Norberg, Vincent Eijsink
  • Patent number: 10155046
    Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: December 18, 2018
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
  • Patent number: 10155045
    Abstract: Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: December 18, 2018
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
  • Patent number: 10144753
    Abstract: The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: December 4, 2018
    Assignee: Produkem Molekulares Design GMBH
    Inventors: Christian R. Noe, Michael Sonntagbauer, Sébastien Queva, Ernst Urban
  • Patent number: 10144756
    Abstract: A process for the preparation of the amorphous form of Regadenoson of formula is disclosed together with new crystalline polymorphic forms E, F and G and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (>99.6%) and high stability to the heating. A particularly thermodynamically stable anhydrous crystalline form of Regadenoson (form G) is also disclosed, provided with high stability not when exposed to 90% RH at 25° C. for 96 hour, but also to the heating up to 200° C.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: December 4, 2018
    Inventors: Paride Grisenti, Elahi Shahrzad Reza, Giuseppe Guazzi, Maria Argese
  • Patent number: 10123992
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 13, 2018
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 10105380
    Abstract: A molecule responding to formula (I) of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by Pseudomonas aeruginosa, more specifically as inhibitors of Pseudomonas aeruginosa's virulence.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: October 23, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER 1
    Inventors: Francois Morvan, Jean-Jacques Vasseur, Caroline Ligeour, Yann Chevolot, Eliane Souteyrand, Olivier Vidal, Alice Goudot, Sebastien Vidal
  • Patent number: 10087242
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: October 2, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTES
    Inventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
  • Patent number: 10071072
    Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 11, 2018
    Assignee: N.V. NUTRICIA
    Inventors: Mattheus Cornelis De Wilde, Johannes Wilhelmus Christina Sijben, Patrick Joseph Gerardus Hendrikus Kamphuis, Robert Johan Joseph Hageman
  • Patent number: 10066026
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: September 4, 2018
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, Ryan Murelli, Andrew Zhang
  • Patent number: 10064883
    Abstract: The present invention relates to a pharmaceutical composition including Lipiodol and a molecule with anti-tumor activity and secondarily a hydroxyethyl starch. The present invention also relates to the use of the compositions according to the invention for treating cancer. According to one embodiment, the pharmaceutical composition according to the invention has between 0.004% and 0.2% by weight of idarubicin, between 0.38% and 2.25% by weight of hydroxyethyl starch and secondarily between 60% and 68% by weight of Lipiodol, and water for injection (or even physiological saline) in a quantity sufficient (q.s.) for 100%.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: September 4, 2018
    Assignee: GUERBET
    Inventors: Boris Guiu, Mathieu Boulin, Jean-Pierre Cercueil